Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages
Stock market LIVE: Sectorally, all the indices were in the green, led by the Nifty Realty index (up 3.5 per cent)
Glenmark and Aurobindo Pharma are recalling multiple products in the US market due to various reasons like deviation from standard manufacturing protocols and presence of foreign substance
Govindarajan has decided to step down due to "personal reasons", Aurobindo Pharma said in a regulatory filing
Drug firm Aurobindo Pharma on Friday said its arm Eugia Pharma Specialities has received approval from the US health regulator for Cyclophosphamide injection, used in the treatment of several types of cancer. The company's subsidiary "Eugia Pharma Specialities Ltd has received a 505(b)(2) NDA approval from the US Food & Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vial," Aurobindo Pharma said in a regulatory filing. The product will be available in ready-to-use injection preparation, it added. "The product shall be launched in the US market in the near term and will be manufactured in Eugia's manufacturing facility in India," Aurobindo Pharma said. According to IQVIA, the approved product has an addressable market size of USD 170 million for the twelve months ending June 2021, it added. Cyclophosphamide Injection is indicated for malignant lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ...
Aurobindo Pharma has corrected over 35 per cent from its lifetime high and has plunged below all its major exponential moving averages
Aurobindo Pharma, on August 12, 2021, had entered into binding agreements with Cronus Pharma Specialities India Private Limited for acquisition of 51 per cent ownership
Market regulator Sebi kept the proposed Rs 4,500-crore initial share-sale of edible oil major Adani Wilmar in "abeyance"
Aurobindo Pharma Ltd on Friday said its Rs 450-crore deal to acquire 51 per cent stake in Cronus Pharma Specialities India Pvt Ltd (Cronus) has been cancelled
The stock of the pharmaceutical company was trading at its lowest level since June 2020
The company has been making small acquisitions to bridge the growth gap
Aurobindo Pharma has entered into definitive agreements under which the Company will subscribe to fresh equity shares in Cronus amounting to Rs 420 crore
Aurobindo Pharma on Thursday reported a 1.68 per cent decline in its consolidated net profit to Rs 769.97 crore for the quarter ended on June 30, 2021, mainly on account of reduction in expenses
The Hyderabad-based drug major is looking to develop products with higher complexity, focus on injectables business and expand business in high growth markets like China.
Separate listing could capture strong growth rates which is not the case in the current structure
The company said the transfer of the business undertaking will be done for a lumpsum consideration of Rs 876 crore
MSTC's stock has been in a consolidation phase for quite some time maintaining the base near 255 levels and currently has given a bullish candle pattern in the daily chart
Marksans Pharma and Novartis India from the S&P BSE Healthcare index zoomed 20 per cent each
Upsides from capex and investments across segments are at least three years away
Bank of Baroda (BoB) reported a standalone net loss of Rs 1,047 crore in the quarter ended March 2021, as it shifted to a new tax regime